| Literature DB >> 29234534 |
Archika Gupta1, Rajesh Gupta2, Punit Srivastav2, Ankush Gupta3.
Abstract
OBJECTIVE: To compare the effect of interrupted- and continuous-suture urethroplasty on complication rates in Snodgrass tubularised incised-plate (TIP) hypospadias repair. PATIENTS AND METHODS: This was a prospective randomised study comprising 100 boys (age range 1-5 years) with primary subcoronal, distal- and mid-penile hypospadias who underwent repair from October 2010 to March 2015 in a tertiary care hospital. Boys with glanular, recurrent, and proximal hypospadias were excluded from the study. The boys were prospectively randomised into two groups: Group A, comprised 50 boys who underwent interrupted subcuticular suture Snodgrass TIP urethroplasty; and Group B, comprised 50 boys who underwent continuous subcuticular suture Snodgrass TIP urethroplasty. Outcomes were assessed in terms of complication rates and aesthetic appearance during follow-up.Entities:
Keywords: CONSORT, Consolidated Standards of Reporting Trials; Hypospadias; Snodgrass TIP repair; TIP, tubularised incised-plate; Urethrocutaneous fistula; Urethroplasty
Year: 2017 PMID: 29234534 PMCID: PMC5717464 DOI: 10.1016/j.aju.2017.10.004
Source DB: PubMed Journal: Arab J Urol ISSN: 2090-598X
Checklist items according to the Consolidated Standards of Reporting Trials (CONSORT) 2010 guidelines.
| Section/topic | Item no. | Checklist item | Reported (Yes/No) |
|---|---|---|---|
| Title and Abstract | 1a | Identification as a randomised trial in the title | Yes |
| 1b | Structured summary of trial design, methods, results, and conclusions | Yes | |
| Introduction | |||
| Background and objectives | 2a | Scientific background and explanation of rationale | Yes |
| 2b | Specific objectives or hypotheses | Yes | |
| Methods | |||
| Trial Design | 3a | Description of trial design (such as parallel, factorial), including allocation ratio | Yes |
| 3b | Important changes to methods after trial commencement (such as eligibility criteria), with reasons | Not done | |
| Participants | 4a | Eligibility criteria for participants | Yes |
| 4b | Settings and locations where the data were collected | Yes | |
| Intervention | 5 | The interventions for each group with sufficient details to allow replication, including how and when they were actually administered | Yes |
| Outcomes | 6a | Completely defined pre-specified primary and secondary outcome measures, including how and when they were assessed | Yes |
| 6b | Any changes to trial outcomes after the trial commenced, with reasons | No | |
| Sample size | 7a | How sample size was determined | On the basis of prior hypospadias repair in same institute |
| 7b | When applicable, explanation of any interim analyses and stopping guidelines | Not required | |
| Randomisation | |||
| Sequence generation | 8a | Method used to generate the random allocation sequence | Simple random sampling with use of computer random table random table |
| 8b | Type of randomisation; details of any restriction (such as blocking and block size) | Simple random sequential randomisation | |
| Allocation concealment mechanism | 9 | Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), describing any steps taken to conceal the sequence until interventions were assigned | Yes |
| Implementation | 10 | Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions | (authors 1 and 2) |
| Blinding | 11a | If done, who was blinded after assignment to interventions (for example, participants, care providers, those assessing outcomes) and how | Blinding was done for outcome assessment |
| 11b | If relevant, description of the similarity of interventions | ||
| Statistical methods | 12a | Statistical methods used to compare groups for primary and secondary outcomes | Yes |
| 12b | Methods for additional analyses, such as subgroup analyses and adjusted analyses | Not done | |
| Results | |||
| Participant flow (a diagram is strongly recommended) | 13a | For each group, the numbers of participants who were randomly assigned, received intended treatment, and were analysed for the primary outcome | Yes |
| 13b | For each group, losses and exclusions after randomisation, together with reasons | Not required | |
| Recruitment | 14a | Dates defining the periods of recruitment and follow-up | Yes |
| 14b | Why the trial ended or was stopped | Completion of study | |
| Baseline data | 15 | A table showing baseline demographic and clinical characteristics for each group | Yes |
| Numbers analysed | 16 | For each group, number of participants (denominator) included in each analysis and whether the analysis was by original assigned groups | Yes |
| Outcomes and estimation | 17a | For each primary and secondary outcome, results for each group, and the estimated effect size and its precision (such as 95% confidence interval) | Estimated in terms of |
| 17b | For binary outcomes, presentation of both absolute and relative effect sizes is recommended | ||
| Ancillary analysis | 18 | Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing pre-specified from exploratory | Not done |
| Harms | 19 | All important harms or unintended effects in each group (for specific guidance, see CONSORT for harms [28]) | No harm occurred |
| Discussion | |||
| Limitations | Trial limitations; addressing sources of potential bias; imprecision; and, if relevant, multiplicity of analyses | Yes | |
| Generalisability | Generalisability (external validity, applicability) of the trial findings | Yes | |
| Interpretation | Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence | Yes | |
| Other Information | |||
| Registration | Registration number and name of trial registry | Not registered | |
| Protocol | Where the full trial protocol can be accessed, if available | No | |
| Funding | Sources of funding and other support (such as supply of drugs), role of funders | No funding |
Fig. 1Study flow showing randomisation of patients.
Incidence of different types of hypospadias in both groups.
| Location | Group A, | Group B, | Total, |
|---|---|---|---|
| Subcoronal | 30 | 38 | 68 |
| Distal penile | 12 | 8 | 20 |
| Mid-penile | 8 | 4 | 12 |
Incidence of complications in both groups.
| Complications | Group A, | Group B, | Total, | |
|---|---|---|---|---|
| Urethrocutaneous fistula | 6 | 7 | 13 | 0.500 |
| Partial superficial wound infection | 1 | 1 | 2 | 0.753 |
| Partial glans dehiscence | 1 | 1 | 2 | 0.753 |
| Meatal stenosis | 1 | 1 | 2 | 0.753 |
| Urethral stricture | 1 | 1 | 2 | 0.753 |
| Total | 10 | 11 | 21 | 0.500 |